They files another S-1 with the SEC that seems to formalize their previously announced plans to enter the NASDAQ without an IPO, with pricing determined by the market -- all seemingly in response to a demand for liquidity by various influential shareholders. The only real "news" here, based a quick skim, is they are setting the baseline share price at $15, until trading commences and the market speaks. At $15/share, most investors from the penny stock days would likely see a gain of 200% - 500%, depending on when you bought. Which would be nice, if it held up. But I don't expect that to hold up initially, as I don't know where the demand will be coming from, given their apparent determination to remain utterly unknown in the marketplace. But you never know. They keep doubling down on the clinical trials starting this year. Should positive early results, or rumors of same, emerge, that could provide a tailwind later this year. But I will believe all of this when I see it.
